DelveInsight’s, “HER2-mutant Non-Small Cell Lung Cancer Pipeline Insight, 2023” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in HER2-mutant Non-Small Cell Lung Cancer pipeline landscape. It covers the HER2-mutant Non-Small Cell Lung Cancer pipeline drug profiles, including HER2-mutant Non-Small Cell Lung Cancer clinical trials and nonclinical stage products. It also covers the HER2-mutant Non-Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive HER2-mutant Non-Small Cell Lung Cancer pipeline products in this space.
In the HER2-mutant Non-Small Cell Lung Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, HER2-mutant Non-Small Cell Lung Cancer NDA approvals (if any), and product development activities comprising the technology, HER2-mutant Non-Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the HER2-mutant Non-Small Cell Lung Cancer Pipeline Report
To explore more information on the latest breakthroughs in the Her2+ Non Small Cell Lung Cancer Pipeline treatment landscape of the report, click here @ Her2+ Non Small Cell Lung Cancer Pipeline Outlook
Her2+ Non Small Cell Lung Cancer Overview
Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancers. NSCLC is one of the most genomically diverse cancers, making it very difficult to treat. For all NSCLC patients who have the adenocarcinoma subtype, testing for alterations in epidermal growth factor receptor (EGFR), mesenchymal epithelial transition factor (MET), b-raf proto-oncogene (BRAF), anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 (ROS1), ret proto-oncogene (RET) and neurotrophic tyrosine receptor kinase (NTRK) is recommended by the National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) guidelines. Non-small-cell lung cancer (NSCLC) harbouring HER2 alterations is now considered a distinct molecular subtype.
Latest Breakthroughs/News for HER2+ Non Small Cell Lung Cancer Treatment Landscape
For further information, refer to the detailed Her2+ Non-Small Cell Lung Cancer Unmet Needs, Her2+ Non-Small Cell Lung Cancer Market Drivers, and Her2+ Non-Small Cell Lung Cancer Market Barriers, click here for Her2+ Non-Small Cell Lung Cancer Ongoing Clinical Trial Analysis
HER2+ Non Small Cell Lung Cancer Emerging Drugs Profile
DZD9008 is a selective, irreversible EGFR inhibitor, which is currently being evaluated for the treatment of both EGFRexon20 insertion mutation-positive NSCLC and HER2-mutated NSCLC. In the open-label, multicenter phase I/II study (NCT03974022), 220 patients with EGFRexon20 insertion mutation-positive or HER2-positive NSCLC were treated with DZD9008 at doses of 50 mg to 400 mg once daily.
Enhertu is a HER2-directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, Enhertu is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced programme in AstraZeneca’s ADC scientific platform. Enhertu consists of a HER2 monoclonal antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a stable tetrapeptide-based cleavable linker. Enhertu (5.4mg/kg) is approved in more than 40 countries for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens based on the results from the DESTINY-Breast01 trial. Enhertu (6.4mg/kg) is approved in several countries for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastro esophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen based on the results from the DESTINY-Gastric01 trial.
Pyrotinib is a novel irreversible and selective EGFR/HER2 tyrosine kinase inhibitor developed by Hengrui. In 2018, pyrotinib was approved in China in combination with capecitabine for the treatment of relapsed or metastatic HER2-positive breast cancer. Currently, two Phase III studies are ongoing to evaluate pyrotinib as 1st-line treatment (NCT03863223) and extended adjuvant treatment (NCT03980054), respectively in HER2-positive breast cancer patients. In addition to breast cancer, pyrotinib demonstrated superior clinical benefits in advanced non-small cell lung cancer (NSCLC) with HER2 exon 20 mutation in a Phase II study. A global Phase III study (NCT04447118) is ongoing to investigate pyrotinib in patients with advanced non-squamous NSCLC with HER2 exon 20 mutation who previously failed platinum-based chemotherapy.
HER2+ Non Small Cell Lung Cancer Pipeline Therapeutics Assessment
There are approx. 5+ key companies which are developing the therapies for HER2-mutant Non-Small Cell Lung Cancer. The companies which have their HER2-mutant Non-Small Cell Lung Cancer drug candidates in the most advanced stage, i.e. Preregistration include, AstraZeneca.
Request a sample and discover the recent advances in Her2+ Non Small Cell Lung Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Her2+ Non Small Cell Lung Cancer Treatment Landscape
Scope of the Her2+ Non-Small Cell Lung Cancer Pipeline Report
Dive deep into rich insights for drugs for HER2-mutant Non-Small Cell Lung Cancer Market Drivers and HER2-mutant Non-Small Cell Lung Cancer Market Barriers, click here @ HER2-mutant Non-Small Cell Lung Cancer Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Her2+ Non Small Cell Lung Cancer Mergers and acquisitions, Her2+ Non Small Cell Lung Cancer Licensing Activities @ Her2+ Non Small Cell Lung Cancer Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsightContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NV 89107Country: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services